Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Reports Stock Transactions
SEC Form 4 Filing
CEO Benjamin Palleiko reports acquisition of shares through stock unit vesting and sales to cover tax obligations.
Summary
- On August 17, 2024, Benjamin Palleiko, CEO of KalVista Pharmaceuticals, acquired 30,195 shares of common stock through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- These transactions included the vesting of 2,418 RSUs from a grant commencing on August 17, 2022, 6,944 RSUs from a grant commencing on November 17, 2022, and 20,833 PSUs from a grant on January 10, 2024.
- On August 19, 2024, Palleiko sold 14,215 shares at a weighted average price of $12.0133 per share to cover tax withholding obligations related to the vesting of the RSUs and PSUs.
- Following these transactions, Palleiko directly owns 242,527 shares of KalVista Pharmaceuticals common stock, along with 16,932 RSUs, 34,723 RSUs, and 20,834 PSUs.
Sentiment
Score: 6
Explanation: Neutral sentiment as the transactions are routine and related to compensation and tax obligations. The vesting suggests performance targets are being met, which is mildly positive.
Positives
- The vesting of RSUs and PSUs indicates that performance metrics were met, which is a positive sign for the company's progress.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors regarding the buying and selling activities of company executives and directors.
Comparison to Industry Standards
- Insider transactions are common in the pharmaceutical industry, particularly related to equity compensation plans.
- Similar to other biotech companies, KalVista uses RSUs and PSUs to incentivize and retain key executives.
- The 'sell to cover' transaction is a standard method for executives to manage tax obligations associated with equity vesting, aligning with practices observed at companies like BioCryst Pharmaceuticals and Ionis Pharmaceuticals.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
- The sale of shares to cover taxes may have a minor impact on the stock price, but is unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 08/17/2022 | Vesting Commencement Date for 1/16th of total shares subject to an RSU, vesting quarterly. |
| 11/17/2022 | Vesting Commencement Date for 1/12th of total shares subject to an RSU, vesting quarterly. |
| 01/10/2024 | Date of PSU grant to the Reporting Person. |
| 02/17/2024 | Vesting Commencement Date for 1/4th of total shares subject to a PSU, vesting quarterly upon achievement of Performance Metrics. |
| 06/30/2024 | Date as of which 2,000 shares were acquired under the Employee Stock Purchase Plan. |
| 08/17/2024 | Date of RSU and PSU vesting. |
| 08/19/2024 | Date of stock sale to cover tax obligations. |
| 08/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.